Mirtazapine Milpharm Limited (Mirtazapine)

Mirtazapine works by blocking central presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine. It also antagonizes 5‑HT2 and 5‑HT3 serotonin receptors and H1 histamine receptors, leading to heightened serotonergic activity and a sedative effect that contributes to its antidepressant properties.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Dosage may be adjusted over time, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for mirtazapine in pregnancy are limited, and the medication is generally not recommended unless the potential benefit outweighs the risk. Mirtazapine is excreted in breast milk, so breastfeeding mothers should discuss alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in greater sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss. However, its side‑effect profile differs, and choice of therapy should be individualized.

Mirtazapine Milpharm Limited should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Mirtazapine is administered orally, typically as a tablet taken once daily, preferably in the evening due to its sedative effect. Patients should swallow the tablet whole with water and follow any specific instructions from their prescriber regarding food intake.

Serious risks include agranulocytosis, severe liver injury, hypersensitivity reactions, and the emergence or worsening of suicidal thoughts, especially in younger adults. Patients should be monitored for signs of infection, liver dysfunction, allergic reactions, and changes in mood or behavior.

Mirtazapine is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) within 14 days, those with known hypersensitivity to the drug, and individuals with severe hepatic impairment without dose adjustment. Caution is also advised for patients with a history of bipolar disorder, as it may precipitate mania.